Lamivudine-15N, d2
Lamivudine-15N, d2 is 15N and deuterated labeled Lamivudine. Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS[1][2].
Product Specifications
Product Name Alternative
BCH-189-15N, d2
UNSPSC
12352005
Target
HBV; HIV; Isotope-Labeled Compounds; Reverse Transcriptase
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Others
Applications
COVID-19-anti-virus
Field of Research
Cancer; Infection
Solubility
10 mM in DMSO
Smiles
OC([2H])([2H])[C@@H]1O[C@H](N2C=CC([15NH2])=NC2=O)CS1.Cl
Molecular Formula
C8H10D2ClN2 15NO3S
Molecular Weight
268.72
References & Citations
[1]Colledge D, et al. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 1997 Jul;26 (1) :216-25. |[2]Olaniyan LW, et al. Lamivudine-Induced Liver Injury. Open Access Maced J Med Sci. 2015 Dec 15;3 (4) :545-50. |[3]Mdanda S, et al. Zidovudine and Lamivudine as Potential Agents to Combat HIV-Associated Neurocognitive Disorder. Assay Drug Dev Technol. 2019 Oct;17 (7) :322-329. |[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog